Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Am Acad Dermatol ; 90(6): 1182-1189, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38341148

ABSTRACT

BACKGROUND: There is no established standard of care for treating central centrifugal cicatricial alopecia (CCCA), and treatment approaches vary widely. OBJECTIVE: To develop consensus statements regarding the use of various pharmacological therapies in treating adults with CCCA. METHODS: We invited 27 dermatologists with expertise in hair and scalp disorders to participate in a 3-round modified Delphi study between January and March 2023. Statements met strong consensus if 75% of respondents agreed or disagreed. Statements met moderate consensus if 55% or more but less than 75% agreed or disagreed. RESULTS: In round 1, 5 of 33 (15.2%) statements met strong consensus, followed by 9 of 28 (32.1%) in round 2. After the final round 3 meeting, strong consensus was reached for 20 of 70 (28.6%) overall statements. Two statements achieved moderate consensus. LIMITATIONS: This study included only English-speaking, US-based dermatologists and did not consider nonpharmacological therapies. CONCLUSION: Despite varying opinions among dermatologists, consensus was reached for several statements to help clinicians manage CCCA. We also highlight areas that lack expert consensus with the goal of advancing research and therapeutic options for CCCA.


Subject(s)
Alopecia , Consensus , Delphi Technique , Humans , Alopecia/therapy , Alopecia/diagnosis , Alopecia/drug therapy , Cicatrix/therapy , Cicatrix/etiology , Dermatologists
2.
Dermatol Surg ; 49(10): 949-955, 2023 10 01.
Article in English | MEDLINE | ID: mdl-37530735

ABSTRACT

BACKGROUND: Follicular unit excision is a favored minimally invasive hair transplantation method. However, it is suboptimal for many patients of African descent because of wide variations in hair and skin characteristics. OBJECTIVE: To evaluate the performance of a skin-responsive follicular unit excision device, which accommodates hair curliness, skin thickness, and firmness in patients of African descent. MATERIALS AND METHODS: The authors retrospectively evaluated patients who underwent scalp follicular unit (FU) excision using a skin-responsive technique at 7 multinational clinics. The preoperative donor grading for the anticipated difficulty used a scale with Class V indicating the highest degree of hair curliness, skin thickness, and firmness. RESULTS: Of 64 eligible patients (45 males and 19 females), 28 had Class V FU excision donor grades. The mean transection rate for all patients was 3%-6%, which was highest in class V patients. Skin thickness and firmness had a greater effect on the maximum transection rate than hair curliness. Only 19 or 18 G punches were used. CONCLUSION: The authors report consistence success of a new skin-responsive FU excision device for all patients of African descent with a mean graft transection rate of less than 10%. The findings support skin thickness and firmness as major influencers of graft attrition rate.


Subject(s)
Hair Follicle , Hair , Male , Female , Humans , Hair Follicle/transplantation , Retrospective Studies , Hair/transplantation , Scalp/surgery , Black People , Tissue and Organ Harvesting , Alopecia/surgery
4.
J Drugs Dermatol ; 12(3): 348-9, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23545921

ABSTRACT

Increased cases of acquired epidermodysplasia verruciformis (EDV) have been reported in patients with human immunodeficiency virus (HIV). With regard to management, there are no randomized controlled trials in either immunocompetent or immunocompromised patients, and only a limited number of anecdotal treatment options. Systemic retinoids, either independently or in combination with other treatment modalities, have been used with limited success, demonstrating transient clinical response and recurrence of lesions after cessation of therapy. We report a case of an HIV-positive patient with acquired EDV who achieved sustained clinical resolution even after discontinuation of oral acitretin by applying topical imiquimod to prevent recurrence of his lesions.


Subject(s)
Acitretin/therapeutic use , Aminoquinolines/therapeutic use , Epidermodysplasia Verruciformis/drug therapy , Immunocompromised Host , Acitretin/administration & dosage , Adjuvants, Immunologic/administration & dosage , Adjuvants, Immunologic/therapeutic use , Administration, Cutaneous , Administration, Oral , Aminoquinolines/administration & dosage , Epidermodysplasia Verruciformis/virology , HIV Infections/complications , Humans , Imiquimod , Keratolytic Agents/administration & dosage , Keratolytic Agents/therapeutic use , Male , Middle Aged , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...